DOCSLIB.ORG

Phyto-Oestrogens and Chaste Tree Berry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phyto-Oestrogens and Chaste Tree Berry omens H f W ea o l l th a Leo et al., J Women’s Health Care 2014, 3:5 n C r a u r e o DOI: 10.4172/2167-0420.1000182 J Journal of Women's Health Care ISSN: 2167-0420 Research Article Open Access Phyto-Oestrogens and Chaste Tree Berry: A New Option in the Treatment of Menopausal Disorders Vincenzo De Leo*, Valentina Cappelli, Alessandra Di Sabatino and Giuseppe Morgante Molecular Medicine and Development Department, Obstetrics and Gynecology Clinic, University of Siena, Italy Abstract For a woman, menopause represents a transitional phase from a fertile to a non-fertile age, in which there is a gradual reduction in ovarian function accompanied by a gradual cessation of oestrogen production. The clinical presentation can involve a series of disorders, including hot flushes with episodes of sweating, particularly at night, palpitations, changes in sleep-wake rhythm, irritability, anxiety and mood changes, vaginal dryness due to a process of progressive atrophy with thinning of the outer and inner labia, reduction of vascularisation and elastic fibres, and decreased sexual desire; subsequently, Many women use alternative therapies to treat hot flushes and other menopausal symptoms. The purpose of this review is to summarize current information on the efficacy and safety of phytoestrogens and the herbal medicine. Given the importance that these symptoms assume for the woman, not only for the perceived quality of life, but also for the increased risk of developing all the diseases, all the treatments adopted for menopausal women are directed primarily to resolving vasomotor disorder Keywords: Menopause; Vasomotor symptoms; Hot flushes; Phyto- fibres, and decreased sexual desire; subsequently, the process of atrophy oestrogens; Magnolia; Chaste tree berry also affects the epidermis with thin, pale skin that is easily susceptible to bacterial and viral infections. A similar condition is observed in the Introduction vagina with a reduction in thickness of the mucosa, which becomes atrophic with reduced vascularisation and results in dyspareunia (Table For a woman, menopause represents a transitional phase from 1) [2]. a fertile to a non-fertile age, in which there is a gradual reduction in ovarian function accompanied by a gradual cessation of oestrogen Among the most important long-term complications, attention production [1]. During this period, women are faced with irregular should be drawn to the loss of minerals and consequent reduction in ovulatory or anovulatory cycles without a systematic progression from bone mass, which is associated with osteopenia and osteoporosis of one to the other. varying degrees and dysfunction and atrophy of the genitourinary tract. With the passage of time, oestrogen deficiency in fact accelerates the The mean age of onset of this phase is 40 to 50 years and it is certainly process of bone demineralisation, as oestrogens promote the absorption the most vulnerable period in a woman’s life in that hormone deficiency of calcium in the intestine and the mineralisation process in bone [3]. causes neuroendocrine changes that constitute the pathophysiological basis of neurovegetative disorders (Figure 1). The most common symptoms of menopause, even when taking into account all the different populations studied, are hot flushes, which The clinical presentation can involve a series of disorders, including affect between 65% and 86.8% of the menopausal female population, hot flushes with episodes of sweating, particularly at night, palpitations, whereas night sweats affect between 65% and 82.1%, insomnia between changes in sleep-wake rhythm, irritability, anxiety and mood changes, 61% and 67.8% and mood changes between 57% and 47.5% [4,5]. vaginal dryness due to a process of progressive atrophy with thinning of the outer and inner labia, reduction of vascularisation and elastic The symptom for which postmenopausal women most frequently visit their doctor for relief is the occurrence of hot flushes [6]. This symptom is present in more than 80% of women entering into physiological menopause, while it affects more than 90% of women who have undergone surgical removal of the ovaries. Menopausal symptoms must not be regarded simply as disorders associated with deterioration in the quality of the life, but also as a risk factor for the development of osteoporosis, as well as cardiovascular diseases and brain deterioration [7,8]. *Corresponding author: Prof Vincenzo De Leo, Molecular Medicine and Development Department, University of Siena, Italy, Tel: +390577233465; Fax: +390577233454; E-mail: [email protected] Received February 26, 2014; Accepted August 14, 2014; Published August 18, 2014 Citation: Leo VD, Cappelli V, Sabatino AD, Morgante G (2014) Phyto-Oestrogens and Chaste Tree Berry: A New Option in the Treatment of Menopausal Disorders. J Women’s Health Care 3: 182. doi:10.4172/2167-0420.1000182 Copyright: © 2014 Leo VD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted Figure 1: Main changes in the neuroendocrine axis in menopause. use, distribution, and reproduction in any medium, provided the original author and source are credited. J Women’s Health Care Volume 3 • Issue 5 • 1000182 ISSN: 2167-0420 JWHC, an open access journal Citation: Leo VD, Cappelli V, Sabatino AD, Morgante G (2014) Phyto-Oestrogens and Chaste Tree Berry: A New Option in the Treatment of Menopausal Disorders. J Women’s Health Care 3: 182. doi:10.4172/2167-0420.1000182 Page 2 of 6 Short-term Medium-term Long-term peripheral vasodilatation and thus returning the system to a state of symptoms symptoms symptoms equilibrium. It is specifically the increase in noradrenaline which − Urogenital disorders − Menstrual irregularity results in sweating and hot flushes in menopausal women with the aim o Vaginal dryness − Hot flushes o Dyspareunia − Osteoporosis of reducing raised body temperature [12]. − Sweating o Urinary incontinence − Cardiovascolar (including at night) − Cutaneous and mucosal atrophy disorders Dopamine also plays an important role in thermoregulation in − Insomnia o Cutaneous hypoelasticity − Atherosclerosis − Anxiety that it too is devoted to maintaining a state of euthermia via the D2 (increased wrinkles) − Alzheimer’s − Depression o Atrophy of the oral mucosa disease receptors. As has long been known, bromocriptine, a dopamine − Asthenia o Eye symptoms agonist, is able to increase the activity of the hypothalamic endogenous − Irritability − Obesity opioid system (β-endorphins) on the mechanisms regulating body Table 1: Schematic representation of the main short-term, medium-term and long- temperature in menopause [13]. In fact, β-endorphins are also involved term symptoms of menopausal women. in thermoregulatory homeostasis and inhibit the noradrenergic neurons below the threshold at which heat loss is activated. During fertile life, oestrogens play an important role in modifying the synthesis, release and metabolism of many neurotransmitters, including dopamine and melatonin, which are responsible for modulating the hypothalamic and limbic systems. It is therefore clear that the decrease in oestrogen levels from the perimenopausal period until overt menopause is accompanied by changes in function of these systems, which is of particular relevance to Figure 2: Heat control system during fertile life and changes in the menopausal woman. thermoregulation and vasomotor stability. The resultant outcome is connected with menopausal symptoms. The menopausal changes therefore induce a temporary imbalance of thermoregulation in the hypothalamus, modulating the homeostasis of the body temperature to values below physiological levels, which are then achieved by the dispersal of heat by means of vasodilatation and profuse sweating. Figure 3: Mechanism of development of hot flushes in menopause. Postmenopausally, the decrease in oestrogens reduces the inhibitory activity of β-endorphins on noradrenaline and causes an A review from 2009 on this subject shows that more severe hot increase in activity of the noradrenergic system but also a reduction flushes can be correlated with rapid bone loss and the subsequent of the dopaminergic system, which is significantly less active than in development of osteoporosis within a short period of time [9]; they premenopausal women (Figures 2 and 3) [7,8]. are also related to a weaker verbal memory [10] and reduced levels of plasma antioxidants, but also to an increased cardiovascular stress All these mechanisms explain the positive effect of hormone response and to changes in blood pressure. therapy, resulting in stimulation of the D2 dopaminergic receptors and the subsequent attenuation of the menopausal symptoms associated The vasomotor symptoms are also correlated with a significant with hot flushes and sweating, with a consequent improvement also increase in the risk of coronary heart disease, which does not appear in the psychological correlations and a decrease in the risk factors for to be entirely explicable by other risk factors for coronary heart disease osteoporotic and cardiovascular diseases. [11]. Melatonin levels and the time during which these levels remain Given the importance that these symptoms assume for the woman, high during the night also differ during the various phases of life, with a not only for the perceived quality of life, but also for the increased risk significant decrease with advancing age; this explains why sleep is often of developing all the diseases listed above,
Load more

Recommended publications
  • Chemoprotective Effects of Flaxseed Lignans Enterodiol And
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Texas A&M Repository CHEMOPROTECTIVE EFFECTS OF FLAXSEED LIGNANS ENTERODIOL AND ENTEROLACTONE IN NON-TRANSFORMED COLONOCYTES A Thesis by CHRISTINA ALISON CURRY Submitted to the Office of Graduate and Professional Studies of Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Chair of Committee, Clinton Allred Committee Members, Joseph Awika Jenna Anding Head of Department, Boon Chew December 2015 Major Subject: Nutrition Copyright 2015 Christina Alison Curry ABSTRACT Previous epidemiological studies have shown that colon cancer incidence is correlated to diet and estrogen status. Phytoestrogens are molecules with similar structures to estrogen that occur naturally in plants. There is in vitro and in vivo evidence that phytoestrogens in the diet can inhibit carcinogenesis. The phytoestrogenic mammalian lignans enterolactone (EL) and enterodiol (ED) in flaxseed have been shown to be effective in decreasing tumor incidence in carcinogenic models, but there is little data regarding their effects in non-malignant cells. The following studies used a non- transformed cell line of young adult mouse colonocytes (YAMC) to determine the protective effects of ED and EL in chemoprevention. Our results demonstrate that low levels of EL (1µM) and ED (5µM) are effective at significantly reducing cell growth and increasing apoptosis. These treatments also regulated transcription via significant differences in gene levels related to apoptosis and cell cycle progression. The data collected demonstrate some of the physiological effects of EL and ED on the cellular and molecular level.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. N0.: US 2014/0221426 A1 Gerk Et Al
    US 20140221426A1 (19) United States (12) Patent Application Publication (10) Pub. N0.: US 2014/0221426 A1 Gerk et al. (43) Pub. Date: Aug. 7, 2014 (54) SELECTIVE METABOLIC APPROACH TO A61K 31/216 (2006.01) INCREASING ORAL BIOAVAILABILITY OF A61K 31/09 (2006.01) PHENYLEPHRINE AND OTHER PHENOLIC A61K 31/05 (2006.01) BIOACTIVITIES A61K 31/353 (2006.01) A61K 31/4525 (2006.01) (71) Applicant: VIRGINIA COMMONWEALTH A61 K 31/3 75 (2006.01) UNIVERSITY, Richmond, VA (US) A61K 31/121 (2006.01) _ _ _ (52) US. Cl. (72) Inventorsl Ph_lll_lP M- Gerk’ Rthmond, VA (Us); CPC ........... .. A61K 31/137 (2013.01); A61K 31/3 75 Wllllam H- Fa", R10hm°nda VA (Us); (2013.01); A61K 31/235 (2013.01); A61K J"sellh K- thter’ Rlchmond, VA (Us) 31/11 (2013.01); A61K 31/085 (2013.01); _ A61K 31/121 (2013.01); A61K 31/09 (21) APP1~ NO" 14/345,689 (2013.01); A61K31/05 (2013.01); A61K . _ 31/353 (2013.01);A61K31/4525 (2013.01); (22) PCT Filed. Sep. 27, 2012 A61K31/216 (201301) USPC ......... .. 514/321' 514/653' 514/474' 514/544' ( 86 ) PCT N 0 .: PCT/U52012/057588 ’ ’ 514/456;’ 514/532’ § 371 (0X1), Related US“ Application Data Presystemic metabolism in intestine of bioactives such as (60) Provisional application No. 61/539,530, ?led on Sep. phenylephrine 1? avoided by administering a Sllbject (human 27, 2011, provisional application No. 61/544,396, 0r 21111111211) the bloactlve(e-g-,Pheny1ephr1ne)1n comblnatlon ?led on Oct 7, 201 1_ With one or more inhibitors of sulfation (e.g., sulfotransferase enzymes aka SULTs).
    [Show full text]
  • Premenstrual Syndrome: a Natural Approach to Management
    CNI506 8/99 Vol. 5, No. 6 APPLIED NUTRITIONAL SCIENCE REPORTS Copyright © 1997 Advanced Nutrition Publications, Inc. rev. 1999 Premenstrual Syndrome: A Natural Approach to Management BY JOSEPH L. MAYO, MD, FACOG ABSTRACT: Premenstrual syndrome (PMS) is a disorder that imbalances, nutritional insufficiencies, and psychologic factors. occurs during the luteal phase of the menstrual cycle, producing A nutritional approach to PMS that takes into account the complex a diverse number of physical and emotional changes. The most interactions of all bodily systems that influence hormonal balance common symptoms of PMS include bloating, backache, breast and neuroendocrine function, with an emphasis on the liver, is tenderness, food cravings, fatigue, irritability, and depression. recommended. The nutritional factors that have been studied The timing of the appearance and disappearance of symptoms, include vitamin B6, magnesium, zinc, choline, vitamin E, and rather than the presence of specific symptoms, is of more essential fatty acids, in addition to weight management and importance in the diagnosis of PMS. The direct cause of PMS is stress reduction. Herbal therapies have also proven beneficial in unknown, although there are numerous theories relating to hormonal the management of PMS. PREMENSTRUAL SYNDROME symptoms such as bloating, breast tenderness, and headache (Table 1).3-5 These diverse symptoms may range from mild Cyclic symptoms in women of reproductive age have been to incapacitating. In some women a single symptom, such recognized for thousands of years. First appearing in the medical as depression, may predominate, whereas others may have literature in 1931 and originally termed “premenstrual tension,” several symptoms.1 this condition has been renamed “premenstrual syndrome” (PMS) in an effort to take into account the different clinical Table.
    [Show full text]
  • Phytoestrogens : Daidzein, Enterodiol, Enterolactone, Equol, Geinstein, O-Desmethylangolensin Matrix: Urine Method: HPLC-ESI-MS/MS Method No: 4069.03
    Laboratory Procedure Manual Analyte: Phytoestrogens : Daidzein, Enterodiol, Enterolactone, Equol, Geinstein, O-Desmethylangolensin Matrix: Urine Method: HPLC-ESI-MS/MS Method No: 4069.03 Revised: March 2018 as performed by: Nutritional Biomarkers Branch (NBB) Division of Laboratory Sciences (DLS) National Center for Environmental Health (NCEH) contact: James L. Pirkle, M.D., Ph.D. Director, Division of Laboratory Sciences Important Information for Users CDC periodically refines these laboratory methods. It is the responsibility of the user to contact the person listed on the title page of each write-up before using the analytical method to find out whether any changes have been made and what revisions, if any, have been incorporated. Phytoestrogen NHANES 2013-2014 This document details the Lab Protocol for testing the items listed in the following table. This method file describes measurements of U1PHYTO_H_R and U2PHYTO_H_R. One method was used to measure both the 24 hour urine phytoestrogen, 1st urine collection and 24 hour urine phytoestrogen, 2nd urine collection. However, these results are released as 2 separate data files. Variable File Name SAS Label (and SI units) Name Daidzein, Urine 1st collection UR1DAZ (ng/mL) o-Desmethylangolensin, Urine 1st UR1DMA Collection (ng/mL) UR1EQU Equol, Urine 1st Collection (ng/mL) Enterodiol, Urine 1st Collection UR1ETD (ng/mL) Enterolactone, Urine 1st Collection UR1ETL (ng/mL) Genistein, Urine 1st Collection UR1GNS (ng/mL) U1PT_H_R Daidzein, Urine 2nd collection U2PT_H_R UR2DAZ (ng/mL) o-Desmethylangolensin, Urine 2nd UR2DMA Collection (ng/mL) UR2EQU Equol, Urine 2nd Collection (ng/mL) Enterodiol, Urine 2nd Collection UR2ETD (ng/mL) Enterolactone, Urine 2nd Collection UR2ETL (ng/mL) Genistein, Urine 2nd Collection UR2GNS (ng/mL) 2 of 54 Phytoestrogen NHANES 2013-2014 1.
    [Show full text]
  • HANDBOOK of Medicinal Herbs SECOND EDITION
    HANDBOOK OF Medicinal Herbs SECOND EDITION 1284_frame_FM Page 2 Thursday, May 23, 2002 10:53 AM HANDBOOK OF Medicinal Herbs SECOND EDITION James A. Duke with Mary Jo Bogenschutz-Godwin Judi duCellier Peggy-Ann K. Duke CRC PRESS Boca Raton London New York Washington, D.C. Peggy-Ann K. Duke has the copyright to all black and white line and color illustrations. The author would like to express thanks to Nature’s Herbs for the color slides presented in the book. Library of Congress Cataloging-in-Publication Data Duke, James A., 1929- Handbook of medicinal herbs / James A. Duke, with Mary Jo Bogenschutz-Godwin, Judi duCellier, Peggy-Ann K. Duke.-- 2nd ed. p. cm. Previously published: CRC handbook of medicinal herbs. Includes bibliographical references and index. ISBN 0-8493-1284-1 (alk. paper) 1. Medicinal plants. 2. Herbs. 3. Herbals. 4. Traditional medicine. 5. Material medica, Vegetable. I. Duke, James A., 1929- CRC handbook of medicinal herbs. II. Title. [DNLM: 1. Medicine, Herbal. 2. Plants, Medicinal.] QK99.A1 D83 2002 615′.321--dc21 2002017548 This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher.
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • Trans-Resveratrol [501-36-0]
    trans-Resveratrol [501-36-0] Review of Toxicological Literature March 2002 trans-Resveratrol [501-36-0] Review of Toxicological Literature Prepared for Scott Masten, Ph.D. National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, North Carolina 27709 Contract No. N01-ES-65402 Submitted by Karen E. Haneke, M.S. Integrated Laboratory Systems P.O. Box 13501 Research Triangle Park, North Carolina 27709 March 2002 Toxicological Summary for trans-Resveratrol [501-36-0] 03/2002 Executive Summary Nomination trans-Resveratrol was nominated for toxicology studies by the National Institute of Environmental Health Sciences (NIEHS) based on the widespread human exposure to resveratrol through natural dietary sources and dietary supplement use, and concern that it has not been sufficiently evaluated for potential toxicological effects. Non-Toxicological Data General Description: trans-Resveratrol is a polyphenol that occurs naturally in grapes, peanuts, and a number of other plants. It is found in foods/drinks made from grapes and peanuts, and also in a number of herbal remedies, both alone and as part of plant extracts. Commercial Availability, Production, and Uses: trans-Resveratrol is produced commercially by several companies. A commercial extraction method involves using alcohol and water to produce trans­ resveratrol from Polygonum cuspidatum. Resveratrol compounds may be produced or extracted for research purposes by treating cell suspension cultures of grapes with a natural substance from a fungus. Resveratrol compounds have long been found in herbal medicines. Health claims of oral dietary supplements containing trans-resveratrol include protection from free-radical damage, inhibition of arthritic inflammation, inhibition of the cyclooxygenase-2 enzyme, protection of blood vessels, protection against cardiovascular disease and cancer, and alleviation of menopausal symptoms.
    [Show full text]
  • Urinary and Serum Concentrations of Seven Phytoestrogens in a Human Reference Population Subset
    Journal of Exposure Analysis and Environmental Epidemiology (2003) 13, 276–282 r 2003 Nature Publishing Group All rights reserved 1053-4245/03/$25.00 www.nature.com/jea Urinary and serum concentrations of seven phytoestrogens in a human reference population subset LIZA VALENTI´ N-BLASINI, BENJAMIN C. BLOUNT, SAMUEL P. CAUDILL, AND LARRY L. NEEDHAM National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA Diets rich in naturally occurring plant estrogens (phytoestrogens) are strongly associated with a decreased risk for cancer and heart disease in humans. Phytoestrogens have estrogenic and, in some cases, antiestrogenic and antiandrogenic properties, and may contribute to the protective effect of some diets. However, little information is available about the levels of these phytoestrogens in the general US population. Therefore, levels of phytoestrogenswere determined in urine (N ¼ 199) and serum (N ¼ 208) samples taken from a nonrepresentative subset of adults who participated in NHANES III, 1988– 1994. The phytoestrogens quantified were the lignans (enterolactone, enterodiol, matairesinol); the isoflavones (genistein, daidzein, equol, O- desmethylangolensin); and coumestrol (urine only). Phytoestrogens with the highest mean urinary levels were enterolactone (512 ng/ml), daidzein(317 ng/ ml), and genistein (129 ng/ml). In serum, the concentrations were much less and the relative order was reversed, with genistein having the highest mean level (4.7 ng/ml), followed by daidzein (3.9 ng/ml) and enterolactone (3.6 ng/ml). Highly significant correlations of phytoestrogen levels in urineand serum samples from the same persons were observed for enterolactone, enterodiol, genistein, and daidzein. Determination of phytoestrogen concentrations in large study populations will give a better insight into the actual dietary exposure to these biologically active compounds in the US population.
    [Show full text]
  • Analytical Reference Standards
    Cerilliant Quality ISO GUIDE 34 ISO/IEC 17025 ISO 90 01:2 00 8 GM P/ GL P Analytical Reference Standards 2 011 Analytical Reference Standards 20 811 PALOMA DRIVE, SUITE A, ROUND ROCK, TEXAS 78665, USA 11 PHONE 800/848-7837 | 512/238-9974 | FAX 800/654-1458 | 512/238-9129 | www.cerilliant.com company overview about cerilliant Cerilliant is an ISO Guide 34 and ISO 17025 accredited company dedicated to producing and providing high quality Certified Reference Standards and Certified Spiking SolutionsTM. We serve a diverse group of customers including private and public laboratories, research institutes, instrument manufacturers and pharmaceutical concerns – organizations that require materials of the highest quality, whether they’re conducing clinical or forensic testing, environmental analysis, pharmaceutical research, or developing new testing equipment. But we do more than just conduct science on their behalf. We make science smarter. Our team of experts includes numerous PhDs and advance-degreed specialists in science, manufacturing, and quality control, all of whom have a passion for the work they do, thrive in our collaborative atmosphere which values innovative thinking, and approach each day committed to delivering products and service second to none. At Cerilliant, we believe good chemistry is more than just a process in the lab. It’s also about creating partnerships that anticipate the needs of our clients and provide the catalyst for their success. to place an order or for customer service WEBSITE: www.cerilliant.com E-MAIL: [email protected] PHONE (8 A.M.–5 P.M. CT): 800/848-7837 | 512/238-9974 FAX: 800/654-1458 | 512/238-9129 ADDRESS: 811 PALOMA DRIVE, SUITE A ROUND ROCK, TEXAS 78665, USA © 2010 Cerilliant Corporation.
    [Show full text]
  • Pharmacological and Therapeutic Effects of Vitex Agnus‑Castus L.: a Review
    Pharmacogn. Rev. PLANT REVIEW A multifaceted peer reviewed journal in the field of Pharmacognosy and Natural Products www.phcogrev.com | www.phcog.net Pharmacological and Therapeutic Effects ofVitex agnus-castus L.: A Review Mina Cheraghi Niroumand, Fatemeh Heydarpour1, Mohammad Hosein Farzaei2,3 Deputy of Persian Medicine, Ministry of Health and Medical Education, Tehran, 1Department of Epidemiology, Faculty of Public Health, Kermanshah University of Medical Sciences, Kermanshah, 2Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, 3Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran ABSTRACT Vitex agnus-castus L., known as the chaste tree, is a small deciduous tree which its fruits have been used for more than 2500 years in ancient Egypt, Greece, Iran, and Rome for a variety of gynecologic problems. It has also been used for its claimed activity in the reduction of libido. The German health authorities have approved the use of V. agnus-castus for menstrual cycle irregularities, premenstrual syndrome, mastalgia, and menopausal disorders. The German Commission E recommended 30–40 mg/day of extract of dried fruit which is standardized based on 0.6% casticin. Scientific studies confirmed several pharmaceutical effects of this medicinal plant including antioxidant, chemopreventive, immunomodulatory and cytotoxicity, tumoricidal, antimutagenic, antimicrobial, antifungal, insect repellant, larvicidal, fracture healing, osteopenic, antinociceptive, opioidergic, antiepileptic, preventing nonalcoholic fat liver disease and oxidative stress, and anti‑inflammatory activities. Adverse effects following by application of this plant are mild and reversible. There are no drug interactions recognized by systematic reviews. Theoretically, chaste tree could interfere with dopaminergic antagonists. In addition, the application of V.
    [Show full text]
  • 1.25 Lignans: Biosynthesis and Function
    1.25 Lignans: Biosynthesis and Function NORMAN G. LEWIS and LAURENCE B. DAVIN Washington State University, Pullman, WA, USA 0[14[0 INTRODUCTION 539 0[14[1 DEFINITION AND NOMENCLATURE 539 0[14[2 EVOLUTION OF THE LIGNAN PATHWAY 531 0[14[3 OCCURRENCE 534 0[14[3[0 Li`nans in {{Early|| Land Plants 534 0[14[3[1 Li`nans in Gymnosperms and An`iosperms "General Features# 536 0[14[4 OPTICAL ACTIVITY OF LIGNAN SKELETAL TYPES AND LIMITATIONS TO THE FREE RADICAL RANDOM COUPLING HYPOTHESIS 536 0[14[5 707? STEREOSELECTIVE COUPLING] DIRIGENT PROTEINS AND E!CONIFERYL ALCOHOL RADICALS 541 0[14[5[0 Diri`ent Proteins Stipulate Stereoselective Outcome of E!Coniferyl Alcohol Radical Couplin` in Pinoresinol Formation 541 0[14[5[1 Clonin` of the Gene Encodin` the Diri`ent Protein and Recombinant Protein Expression in Heterolo`ous Systems 543 0[14[5[2 Sequence Homolo`y Comparisons 543 0[14[5[3 Comparable Systems 543 0[14[5[4 Perceived Biochemical Mechanism of Action 546 0[14[6 PINORESINOL METABOLISM AND ASSOCIATED METABOLIC PROCESSES 547 0[14[6[0 Sesamum indicum] "¦#!Piperitol\ "¦#!Sesamin\ and "¦#!Sesamolinol Synthases 547 0[14[6[1 Magnolia kobus] Pinoresinol and Pinoresinol Monomethyl Ether O!Methyltransferase"s# 550 0[14[6[2 Forsythia intermedia and Forsythia suspensa 551 0[14[6[2[0 "¦#!Pinoresinol:"¦#!lariciresinol reductase 552 0[14[6[2[1 "−#!Secoisolariciresinol dehydro`enase 554 0[14[6[2[2 Matairesinol O!methyltransferase 556 0[14[6[3 Linum usitatissimum] "−#!Pinoresinol:"−#!Lariciresinol Reductase and "¦#!Secoisolariciresinol Glucosyltransferase"s# 557
    [Show full text]
  • ANTIOXIDANT PROPERTIES of FLAXSEED LIGNANS USING in VITRO MODEL SYSTEMS a Thesis Submitted to the College of Graduate Studies A
    ANTIOXIDANT PROPERTIES OF FLAXSEED LIGNANS USING IN VITRO MODEL SYSTEMS A Thesis Submitted to the College of Graduate Studies and Research in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the College of Pharmacy and Nutrition of the University of Saskatchewan Saskatoon, Saskatchewan Canada By Farah Hosseinian Copyright Farah Hosseinian April 2006 All Rights Reserved The author claims copyright. Use shall not be made of the material contained herein without proper acknowledgment, as indicated on the copyright page. i PERMISION TO USE In presenting this thesis in partial fulfillment of the requirements for a Postgraduate degree from the University of Saskatchewan, I agree that the Libraries of this University may make it freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their absence, by the Dean of the College in which my thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use made of any material in my thesis. Requests for permission to copy or to make other use of material in this thesis, in whole or in parts, should be addressed to: Head College of Pharmacy and Nutrition University of Saskatchewan 110 Science Place Saskatoon, SK S7N 5C9 Canada ii 1.0 ABSTRACT The major objectives of this study were to investigate the antioxidant properties of flaxseed lignans secoisolariciresinol (SECO 2) and secoisolariciresinol diglycoside (SDG 1) and their major oxidative compounds using 2,2'-azobis(2- amidinopropane) dihydrochloride (AAPH 47) in an in vitro model of lipid peroxidation.
    [Show full text]